IL17A and COVID-19: While, both IL-6 and IL-10, as well as serum IL-17A, showed an increasing trend in severe COVID-19 patients after one week of hospitalization suggesting that, in more severe patients, the inflammatory status and the release of cytokines is a more prolonged phenomenon [26,27].